LU177 - pluvicto/lutathera
Active Awarded Last action
- Contract number
- 36C25726N0205
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 17
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $4,162,659
Award facts
- Contract value 100% obligated
- $4,162,659.22 Current and potential, with all options
- Completion date 70% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
About this award
Novartis Pharmaceuticals Corporation was awarded a delivery order valued at $4.16M by Veterans Integrated Service Network 17 (VISN 17) for the supply of LU177 radiopharmaceutical products, specifically PLUVICTO (Lutetium Lu-177 Vipivotide Tetra) and LUTATHERA (Lutetium Lu-177 dotatate). The contract, issued on February 7, 2026, with completion targeted for February 6, 2027, operates under a firm fixed-price structure without small business set-aside designation. This delivery order is issued under Novartis' existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and leverages the company's broader indefinite delivery vehicles established with the Department of Veterans Affairs and Defense Health Agency for specialized oncology and nuclear medicine treatments.
The award reflects Novartis' established role as a primary federal supplier of advanced cancer therapies to the Veterans Health Administration, supporting the VA's mission to provide innovative treatment options to the veteran population. Performance will occur at the contractor's East Hanover, New Jersey facility. PLUVICTO and LUTATHERA are radiopharmaceutical therapies used in advanced cancer treatment, addressing the federal healthcare system's need for specialized and innovative oncology products that support precision medicine approaches in veteran care programs.
Quick answers
Who was awarded contract 36C25726N0205?
36C25726N0205 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 17 (Veterans Health Administration) on February 7, 2026.
How much is contract 36C25726N0205 worth?
The government has obligated $4,162,659 on 36C25726N0205.
Is contract 36C25726N0205 an order under another contract?
Yes. 36C25726N0205 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25726N0205 competed?
The extent of competition for 36C25726N0205 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award